Recent Company News

• 11:49 AM ET Oct 07, 2026
  

  Novartis announces FDA approves Rhapsido (remibrutinib) as first treatment for symptomatic dermographism (SD) (CHF 120.02, 0.00)

• 07:05 AM ET Oct 07, 2026
  

  Novartis to present new data from its multiple sclerosis (MS) portfolio with 46 abstracts at MSToronto2026 (CHF 118.66, +1.48)

• 10:59 AM ET Oct 06, 2026
  

  StreetAccount Sector Summary - China Healthcare September Recap

• 07:33 AM ET Oct 06, 2026
  

  BridgeBio announces FDA acceptance and priority review of NDA for oral infigratinib for children with achondroplasia ($66.14, 0.00)

• 02:01 PM ET Oct 05, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 28-Sep

• 09:57 AM ET Oct 05, 2026
  

  StreetAccount M&A Summary: Week of 28-Sep

• 11:19 AM ET Oct 03, 2026
  

  Trump announces Medicare improvement fund payments for seniors

• 06:21 AM ET Oct 02, 2026
  

  StreetAccount Macro Headlines:

• 08:00 PM ET Oct 01, 2026
  

  Abogen Biosciences out-licenses RNA-encoded therapeutics to Novartis for upfront $575M (CHF 117.90, -0.16)

• 05:12 PM ET Oct 01, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market